Unraveling the PAF-AH/Lp-PLA2controversy

To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase

(2014) Gopal Kedihitlu Marathe et al.   JOURNAL OF LIPID RESEARCH

GSK's darapladib failures dim hopes for anti-inflammatory heart drugs

(2014) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity in Japanese Dyslipidemic Patients, With Exploratory Analysis of a PLA2G7 Gene Polymorphism of Val279Phe

(2013) Hiroyuki Daida et al.   CIRCULATION JOURNAL

Generation of membrane diversity by lysophospholipid acyltransferases

(2013) H. Shindou et al.   JOURNAL OF BIOCHEMISTRY

Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes

(2012) Héctor M. García-García et al.   ATHEROSCLEROSIS

Phospholipase A 2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes

(2012) Sung Kee Ryu et al.   CIRCULATION

Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy: An Analysis from the JUPITER Trial

(2012) P. M. Ridker et al.   CLINICAL CHEMISTRY

Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

(2012) Robert S. Rosenson et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein-Associated Phospholipase A2 Activity Predicts Cardiovascular Events in High Risk Coronary Artery Disease Patients

(2012) Giuseppe Maiolino et al.   PLoS One

The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice

(2011) Miao-miao Hu et al.   ACTA PHARMACOLOGICA SINICA

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

(2011) Michelle L. O'Donoghue et al.   AMERICAN HEART JOURNAL

Inhibition of Lipoprotein-Associated Phospholipase A2 Ameliorates Inflammation and Decreases Atherosclerotic Plaque Formation in ApoE-Deficient Mice

(2011) Wen-yi Wang et al.   PLoS One

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

(2010) Harvey White et al.   AMERICAN HEART JOURNAL

Phospholipase A2s: Developing drug targets for atherosclerosis

(2010) Keith Suckling   ATHEROSCLEROSIS

Circulating Platelet-Activating Factor Is Primarily Cleared by Transport, Not Intravascular Hydrolysis by Lipoprotein-Associated Phospholipase A 2 / PAF Acetylhydrolase

(2010) Jinbo Liu et al.   CIRCULATION RESEARCH

Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes

(2010) Harvey White   CURRENT OPINION IN CARDIOLOGY

Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

(2010)   LANCET

Metabolism and atherogenic disease association of lysophosphatidylcholine

(2009) Gerd Schmitz et al.   ATHEROSCLEROSIS

Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)

(2008) Diana M. Stafforini   CARDIOVASCULAR DRUGS AND THERAPY

Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

(2008) Patrick W. Serruys et al.   CIRCULATION

The emerging roles of PAF acetylhydrolase

(2008) Thomas M. McIntyre et al.   JOURNAL OF LIPID RESEARCH

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent

(2008) Emile R. Mohler et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population

(2008) Lori B. Daniels et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

(2008) Robert L Wilensky et al.   NATURE MEDICINE